1.08 USD
▼-0.04-3.57%
盘后 1.31 0.00%
2026-09-16
市值
$44.31M
市盈率
—
EPS
-1.79
股息率
—
52 周区间
1.08 – 5.50
成交量
1.10M
Beta
1.24
目标价
10.50
52W 低 1.0852W 高 5.50
价格走势
公司简介
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company’s lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer’s disease, as well as in open-label phase 3 to treat parkinson’s disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer’s disease an...